1. Home
  2. TBBK vs NVCR Comparison

TBBK vs NVCR Comparison

Compare TBBK & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TBBK
  • NVCR
  • Stock Information
  • Founded
  • TBBK 1999
  • NVCR 2000
  • Country
  • TBBK United States
  • NVCR Switzerland
  • Employees
  • TBBK N/A
  • NVCR 1488
  • Industry
  • TBBK Major Banks
  • NVCR Medical/Dental Instruments
  • Sector
  • TBBK Finance
  • NVCR Health Care
  • Exchange
  • TBBK Nasdaq
  • NVCR Nasdaq
  • Market Cap
  • TBBK 2.4B
  • NVCR 2.0B
  • IPO Year
  • TBBK 2004
  • NVCR 2015
  • Fundamental
  • Price
  • TBBK $51.07
  • NVCR $16.69
  • Analyst Decision
  • TBBK Buy
  • NVCR Buy
  • Analyst Count
  • TBBK 3
  • NVCR 6
  • Target Price
  • TBBK $65.33
  • NVCR $32.83
  • AVG Volume (30 Days)
  • TBBK 475.5K
  • NVCR 1.6M
  • Earning Date
  • TBBK 07-24-2025
  • NVCR 07-24-2025
  • Dividend Yield
  • TBBK N/A
  • NVCR N/A
  • EPS Growth
  • TBBK 20.50
  • NVCR N/A
  • EPS
  • TBBK 4.42
  • NVCR N/A
  • Revenue
  • TBBK $502,282,000.00
  • NVCR $621,711,000.00
  • Revenue This Year
  • TBBK N/A
  • NVCR $5.56
  • Revenue Next Year
  • TBBK $6.71
  • NVCR $9.19
  • P/E Ratio
  • TBBK $11.56
  • NVCR N/A
  • Revenue Growth
  • TBBK 10.02
  • NVCR 18.27
  • 52 Week Low
  • TBBK $33.77
  • NVCR $14.17
  • 52 Week High
  • TBBK $65.84
  • NVCR $34.13
  • Technical
  • Relative Strength Index (RSI)
  • TBBK 48.64
  • NVCR 43.44
  • Support Level
  • TBBK $49.66
  • NVCR $17.20
  • Resistance Level
  • TBBK $51.43
  • NVCR $18.02
  • Average True Range (ATR)
  • TBBK 1.43
  • NVCR 1.04
  • MACD
  • TBBK -0.21
  • NVCR -0.09
  • Stochastic Oscillator
  • TBBK 36.77
  • NVCR 15.51

About TBBK The Bancorp Inc

The Bancorp Inc is a financial holding company. The Company's operations are classified under three segments: fintech, specialty finance (three sub-segments), and corporate. The fintech segment includes the deposit balances and non-interest income generated by prepaid, debit, and other card-accessed accounts, ACH processing, and other payments-related processing. It also includes loan balances and interest and non-interest income from credit products generated through payment relationships; Specialty finance includes REBL (real estate bridge lending) comprised of apartment building rehabilitation loans, and Others; Corporate includes the Company's investment securities, corporate overhead, and expenses which have not been allocated to segments.

About NVCR NovoCure Limited

NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.

Share on Social Networks: